Composition for treating vertigo and preparation method thereof

Through the combination of flucinarizine-anisolamine hydrobromide-betastic eutectic and ginkgo organic extract, the existing drug solubility and stability problems have been solved, and higher bioavailability and therapeutic effects have been achieved. Improves cervical vertigo symptoms.

CN118976079APending Publication Date: 2024-11-19XIAN TRADITIONAL CHINESE MEDICINE ENCEPHALOPATHY HOSPITAL CO LTD
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202411066961.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-05
Publication Date
2024-11-19

AI Technical Summary

Technical Problem

Existing drugs for treating vertigo such as fluburinirazine, anisolamine hydrobromide and betastine have poor solubility, low bioavailability and stability problems, making it difficult to effectively improve the symptoms of cervical vertigo, and Chinese medicine enzyme extraction It is costly and dynamic and difficult to achieve industrial application.

Method used

The combination of fluburinrizine-anisolamine hydrobromide-betastine eutectics and ginkgo organic extracts was used to extract enzymatic ionic liquids with metal ion-modified complex enzymes and ethyl acetate extraction to prepare the treatment of vertigo by combining fluburinrizine-anisolamine-betastine eutectic eluent and genomic extracts. The composition of the composition synergistically plays the role of dilating blood vessels, improving blood supply and protecting cells.

Benefits of technology

It improves the solubility and bioavailability of the drug, enhances the efficacy, reduces adverse reactions, and can smoothly pass the blood-brain barrier, protect endothelial cells, improves blood circulation in the vestibular organs, and significantly reduces vertigo symptoms.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004979709790000211
    Figure BDA0004979709790000211
  • Figure BDA0004979709790000221
    Figure BDA0004979709790000221
Patent Text Reader

Abstract

The invention provides a composition for treating vertigo and a preparation method thereof, and belongs to the technical field of medicines. The preparation method of the flunarizine-anisodamine hydrobromide-betahistine pharmaceutical co-crystal comprises the following steps: degreasing and depigmenting ginkgo leaves, extracting by using a metal ion modified compound enzyme enzymatic ionic liquid, extracting by using ethyl acetate to obtain a ginkgo organic extract, extracting salvia miltiorrhiza and gastrodia elata by using an extraction solvent to obtain an extract, and preparing the flunarizine-anisodamine hydrobromide-betahistine pharmaceutical co-crystal. And uniformly mixing with the ginkgo biloba organic extract and the eutectic crystal to prepare the composition for treating dizziness. The prepared composition for treating dizziness can dilate blood vessels, enhance blood flow, improve blood supply between the brain and the inner ear and protect cells from oxidative damage, all the components are in synergistic effect, vestibular nerve cells are protected so as to improve symptoms such as dizziness, and the composition has wide application prospects.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of medicines, and in particular to a composition for treating vertigo and a preparation method thereof. Background Art

[0002] Cervical vertigo (CV) is caused by functional degeneration or organic changes in the cervical spine and its accessory structures (joint capsules, ligaments, blood vessels, muscles, nerves, etc.), which stimulate and compress the vertebral basilar artery or the sympathetic nerves that control the artery, and then cause ischemia, circulatory disorders and intracranial blood supply insufficiency of the vertebral artery (left and right vertebral arteries, vertebral basilar artery) system. The clinical manifestations are mainly paroxysmal vertigo, which may be accompanied by dizziness, headache, neck pain, visual impairment and even cataplexy. Therefore, cervical vertigo is also called vertebral basilar insufficiency vertigo (VBIV) or vertebral artery cervical spondylosis.

[0003] The TCM community believes that cervical vertigo belongs to the category of "vertigo", "headache" and "arthritis" in traditional Chinese medicine. From the perspective of TCM, its etiology and pathogenesis can be summarized as follows: (1) phlegm and turbidity blocking the middle; (2) wind and yang disturbance; (3) qi and blood deficiency; (4) liver and kidney deficiency; (5) blood stasis blocking the orifices. At present, TCM treatment of vertigo mainly focuses on calming the liver and suppressing yang, resolving phlegm and opening the orifices. Summary of the invention

[0004] The purpose of the present invention is to provide a composition for treating vertigo and a preparation method thereof, which can dilate blood vessels, enhance blood flow, improve blood supply between the brain and the inner ear, and protect cells from oxidative damage. The components work synergistically to protect vestibular nerve cells, thereby improving symptoms such as vertigo, and have broad application prospects.

[0005] The technical solution of the present invention is achieved in this way:

[0006] The invention provides a method for preparing a composition for treating vertigo. The method comprises the following steps: preparing flunarizine-anisodamine hydrobromide-betahistine drug cocrystals, wherein ginkgo leaves are defatted and depigmented, and then extracted with a metal ion-modified composite enzyme catalyzed ionic liquid, and then extracted with ethyl acetate to obtain a ginkgo organic extract, and then extracting salvia miltiorrhiza and gastrodia elata with an extraction solvent to obtain an extract, and uniformly mixing the extract with the ginkgo organic extract and the cocrystal to obtain a composition for treating vertigo.

[0007] As a further improvement of the present invention, the following steps are included:

[0008] S1. dissolving flunarizine in ethanol, dissolving anisodamine hydrobromide and betahistine in water, mixing the two evenly, evaporating the solvent in an open manner, filtering, washing, drying, and ball milling to obtain a drug cocrystal;

[0009] S2. The ginkgo leaves were dried, crushed, and degreased and depigmented by adding a mixed solvent in a Soxhlet extractor, filtered, and dried to obtain a pretreated ginkgo leaf powder;

[0010] S3. The cellulase and pectinase were mixed into water, manganese ions and calcium ions were added, the mixture was stirred and evenly mixed, and freeze-dried to obtain a modified composite enzyme;

[0011] S4. The pretreated ginkgo leaf powder is added to the ionic liquid, the modified complex enzyme is added, the extraction is heated and stirred, the filtrate is added to ethyl acetate, the extraction is shaken, the layers are allowed to stand, the layers are separated, and the solvent is removed from the ethyl acetate layer under reduced pressure to obtain an organic extract of ginkgo;

[0012] S5. The Danshen and Gastrodia elata were mixed and dried, crushed, added to the extraction solvent, heated and stirred for extraction, filtered, the liquid was concentrated, and dried to obtain an extract;

[0013] S6. Evenly mix the drug co-crystal, ginkgo organic extract and extract to prepare a composition for treating vertigo.

[0014] As a further improvement of the present invention, the mass ratio of flunarizine, anisodamine hydrobromide and betahistine in step S1 is 10:3-5:2-4.

[0015] As a further improvement of the present invention, the mixed solvent in step S2 is a mixed solvent of acetone, ethanol and water, with a volume ratio of 1:1-2:10, and the degreasing and depigmenting time is 1-2h.

[0016] As a further improvement of the present invention, in step S3, the manganese ion is manganese chloride, the calcium ion is calcium chloride, and the mass ratio of the cellulase, pectinase, manganese chloride and calcium chloride is 15-20:7-12:0.3-0.4:0.1-0.5.

[0017] As a further improvement of the present invention, the ionic liquid in step S4 is an aqueous solution of 1-butyl-3-methylimidazolium chloride or 1-ethyl-3-methylimidazolium bromide with a concentration of 5-10 g / L, the mass ratio of the pretreated ginkgo leaf powder, the ionic liquid, and the modified composite enzyme is 10:30-50:2-3, the temperature of the heated and stirred extraction is 50-60°C, and the time is 3-4h.

[0018] As a further improvement of the present invention, the mass ratio of Salvia miltiorrhiza and Gastrodia elata in step S5 is 10:12-15, the extraction solvent is a mixed solvent of n-butanol, ethyl acetate and water in a volume ratio of 5-7:3-5:10, and the temperature of the heating and stirring extraction is 65-75°C and the time is 1-3h.

[0019] As a further improvement of the present invention, the mass ratio of the drug co-crystal, the ginkgo organic extract and the extract in step S6 is 1-2:12-15:7-10.

[0020] As a further improvement of the present invention, the present invention specifically comprises the following steps:

[0021] S1. Dissolve 10 parts by weight of flunarizine in ethanol, dissolve 3-5 parts by weight of anisodamine hydrobromide and 2-4 parts by weight of betahistine in water, mix the two evenly, evaporate the solvent in an open state, filter, wash, dry, and ball-mill to obtain a drug cocrystal;

[0022] S2. The ginkgo leaves were dried, crushed, and degreased and depigmented by adding a mixed solvent in a Soxhlet extractor for 1-2h, filtered, and dried to obtain pretreated ginkgo leaf powder;

[0023] The mixed solvent is a mixed solvent of acetone, ethanol and water, with a volume ratio of 1:1-2:10;

[0024] S3. 15-20 parts by weight of cellulase and 7-12 parts by weight of pectinase were mixed into water, 0.3-0.4 parts by weight of manganese chloride and 0.1-0.5 parts by weight of calcium chloride were added, stirred and mixed, and freeze-dried to obtain a modified composite enzyme;

[0025] S4. Add 10 parts by weight of pretreated ginkgo leaf powder to 30-50 parts by weight of ionic liquid, add 2-3 parts by weight of modified complex enzyme, heat to 50-60°C, stir and extract for 3-4h, filter, add an equal volume of ethyl acetate to the filtrate, shake and extract, let stand to separate, separate the layers, remove the solvent from the ethyl acetate layer under reduced pressure, and obtain an organic extract of ginkgo;

[0026] S5. 10 parts by weight of Danshen, 12-15 parts by weight of Gastrodia elata were mixed and dried, crushed, added to the extraction solvent, heated to 65-75 ° C, stirred for extraction for 1-3h, filtered, the liquid was concentrated, and dried to obtain an extract;

[0027] The extraction solvent is a mixed solvent of n-butanol, ethyl acetate and water, with a volume ratio of 5-7:3-5:10;

[0028] S6. Evenly mix 1-2 parts by weight of the drug co-crystal, 12-15 parts by weight of the ginkgo organic extract and 7-10 parts by weight of the extract to prepare a composition for treating vertigo.

[0029] The present invention further protects a composition for treating vertigo obtained by the above preparation method.

[0030] The present invention has the following beneficial effects:

[0031] Flunarizine can effectively reduce the duration and frequency of migraine vertigo symptoms, and can further relieve patients' vertigo symptoms, improve quality of life, and improve sleep. However, it often has poor water solubility, low solubility, and poor bioavailability. Anisodamine hydrobromide is a type of cholinergic inhibitor that can act on microcirculation by exerting anti-adrenergic M receptors, improving the function of patients' vascular endothelial cells and tissue blood supply, but it has problems such as easy deliquescence. Betahistine is a histamine drug that delays the action time of histamine substances and exerts the effect of vasodilation, effectively improving patients' vertigo symptoms, but it also has problems such as poor stability. The present invention forms drug co-crystals by co-crystallizing the above drugs, which not only greatly improves the solubility and bioavailability of the drugs, improves the stability of the drugs, but also reduces the adverse reactions caused by drug residues, and has good safety. In addition, the drug co-crystals are unexpectedly found to enhance the therapeutic effect under synergistic effects. They can smoothly pass through the blood-brain barrier, protect endothelial cells, reduce cytotoxicity, increase cochlear blood flow, improve vestibular organ blood circulation, inhibit the release process of neurotransmitters, and have a good preventive effect on the occurrence of vertigo symptoms.

[0032] Cellulase and pectinase can promote the cell wall breaking of Ginkgo biloba plant cells, but there are problems such as high enzyme prices and difficulty in realizing industrial application. Therefore, the present invention uses metal ions to activate the complex enzyme. Manganese ions have a promoting effect on cellulase and pectinase, and have an activating effect on cellulase activity, and calcium ions can improve the activity of endocellulose. Therefore, under the synergistic effect of metal ions in appropriate doses, the activity of cellulase and pectinase can be greatly improved, which not only reduces the preparation cost, but also can improve enzymolysis and extraction efficiency. After enzyme catalysis, the ionic liquid greatly improves the extraction rate of active ingredients in Ginkgo biloba, and the extraction time and extraction temperature are also significantly shortened.

[0033] The ginkgo organic extract prepared by the present invention includes phenolic compounds, ginkgo ketones, ginkgo flavonoid glycosides, ginkgo lactones, etc., which can scavenge free radicals, antagonize platelet activating factor, resist oxidation, promote lipid metabolism and other special pharmacological effects, and has the functions of improving microcirculation, improving hair cell function, regulating blood rheology parameters, etc., effectively improving peripheral microcirculation, thereby achieving a therapeutic effect.

[0034] Danshen can inhibit platelet aggregation, improve collective anticoagulant and fibrinolytic activity, reduce blood viscosity, inhibit the formation of extracorporeal thrombus, dilate blood vessels, and reduce cerebrovascular resistance. Gastrodia elata has the effects of dredging collaterals, relieving pain, calming the liver and suppressing yang, dilating blood vessels, increasing peripheral vascular compliance, and reducing cerebrovascular resistance. The two can work together to dilate blood vessels, reduce peripheral vascular resistance, increase blood flow, reduce blood lipids, reduce cholesterol, reduce blood viscosity, scavenge free radicals and other functions, reduce nausea, vomiting and sleep disorders caused by imbalance of balance function, relieve symptoms of dizziness, and make the drug work better.

[0035] The composition for treating vertigo prepared by the present invention can dilate blood vessels, enhance blood flow, improve blood supply between the brain and the inner ear, and protect cells from oxidative damage. The components work synergistically to protect vestibular nerve cells, thereby improving symptoms such as vertigo, and has broad application prospects. DETAILED DESCRIPTION

[0036] The technical solutions in the embodiments of the present invention are described clearly and completely below. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of them. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0037] Cellulase, 50,000 U / g, was purchased from Nanning Dongheng Huadao Biotechnology Co., Ltd.

[0038] Pectinase, 5,000 U / g, was purchased from Nanning Dongheng Huadao Biotechnology Co., Ltd.

[0039] 1-Butyl-3-methylimidazolium chloride or 1-ethyl-3-methylimidazolium bromide were analytically pure and were purchased from Shanghai MacLean Biochemical Technology Co., Ltd.

[0040] Example 1

[0041] This embodiment provides a method for preparing a composition for treating vertigo, comprising the following steps:

[0042] S1. Dissolve 10 g of flunarizine in 200 mL of ethanol, and dissolve 3 g of scopolamine hydrobromide and 2 g of betahistine in 200 mL of water, mix the two evenly, evaporate the solvent in an open air, filter, wash, dry, and ball-mill for 1 h to obtain a drug cocrystal;

[0043] S2. The ginkgo leaves were dried, crushed, and degreased and depigmented by adding a mixed solvent in a Soxhlet extractor for 1 h, filtered, and dried to obtain pretreated ginkgo leaf powder;

[0044] The mixed solvent is a mixed solvent of acetone, ethanol and water, with a volume ratio of 1:1:10;

[0045] S3. 15 g of cellulase and 7 g of pectinase were mixed into 500 mL of water, 0.3 g of manganese chloride and 0.1 g of calcium chloride were added, stirred and mixed for 20 min, and freeze-dried to obtain a modified composite enzyme;

[0046] S4. Add 10 g of pretreated ginkgo leaf powder to 30 g of ionic liquid, add 2 g of modified complex enzyme, heat to 50 ° C, stir and extract for 3 h, filter, add an equal volume of ethyl acetate to the filtrate, shake and extract, let stand to separate, separate the layers, remove the solvent from the ethyl acetate layer under reduced pressure to obtain a ginkgo organic extract;

[0047] The ionic liquid is an aqueous solution of 1-butyl-3-methylimidazolium chloride with a concentration of 5 g / L;

[0048] S5. 10 g of Danshen and 12 g of Gastrodia were mixed and dried, crushed, added to 200 mL of extraction solvent, heated to 65 ° C, stirred for extraction for 1 h, filtered, the liquid was concentrated, and dried to obtain an extract;

[0049] The extraction solvent is a mixed solvent of n-butanol, ethyl acetate and water in a volume ratio of 5:3:10;

[0050] S6. Stir and mix 1 g of drug co-crystal, 12 g of Ginkgo organic extract and 7 g of extract for 15 minutes to prepare a composition for treating vertigo.

[0051] Example 2

[0052] This embodiment provides a method for preparing a composition for treating vertigo, comprising the following steps:

[0053] S1. Dissolve 10 g of flunarizine in 200 mL of ethanol, and dissolve 5 g of anisodamine hydrobromide and 4 g of betahistine in 200 mL of water, mix the two evenly, evaporate the solvent in an open air, filter, wash, dry, and ball-mill for 1 h to obtain a drug cocrystal;

[0054] S2. The ginkgo leaves were dried, crushed, and degreased and depigmented by adding a mixed solvent in a Soxhlet extractor for 2 h, filtered, and dried to obtain pretreated ginkgo leaf powder;

[0055] The mixed solvent is a mixed solvent of acetone, ethanol and water, with a volume ratio of 1:2:10;

[0056] S3. 20 g of cellulase and 12 g of pectinase were mixed into 500 mL of water, 0.4 g of manganese chloride and 0.5 g of calcium chloride were added, stirred for 20 min, and freeze-dried to obtain a modified composite enzyme;

[0057] S4. Add 10 g of pretreated ginkgo leaf powder to 50 g of ionic liquid, add 3 g of modified complex enzyme, heat to 60 ° C, stir and extract for 4 h, filter, add an equal volume of ethyl acetate to the filtrate, shake and extract, let stand to separate, separate the layers, remove the solvent from the ethyl acetate layer under reduced pressure to obtain an organic extract of ginkgo;

[0058] The ionic liquid is an aqueous solution of 1-ethyl-3-methylimidazolium bromide with a concentration of 10 g / L;

[0059] S5. 10 g of Danshen and 15 g of Gastrodia were mixed and dried, crushed, added to 200 mL of extraction solvent, heated to 75 ° C, stirred and extracted for 3 h, filtered, the liquid was concentrated, and dried to obtain an extract;

[0060] The extraction solvent is a mixed solvent of n-butanol, ethyl acetate and water in a volume ratio of 7:5:10;

[0061] S6. Stir and mix 2 g of drug cocrystal, 15 g of Ginkgo organic extract and 10 g of extract for 15 minutes to prepare a composition for treating vertigo.

[0062] Example 3

[0063] This embodiment provides a method for preparing a composition for treating vertigo, comprising the following steps:

[0064] S1. Dissolve 10 g of flunarizine in 200 mL of ethanol, dissolve 4 g of scopolamine hydrobromide and 3 g of betahistine in 200 mL of water, mix the two evenly, evaporate the solvent in an open container, filter, wash, dry, and ball-mill for 1 h to obtain a drug cocrystal;

[0065] S2. The ginkgo leaves were dried, crushed, and degreased and depigmented by adding a mixed solvent in a Soxhlet extractor for 1.5 h, filtered, and dried to obtain pretreated ginkgo leaf powder;

[0066] The mixed solvent is a mixed solvent of acetone, ethanol and water, with a volume ratio of 1:1.5:10;

[0067] S3. 17 g of cellulase and 10 g of pectinase were mixed into 500 mL of water, 0.35 g of manganese chloride and 0.3 g of calcium chloride were added, stirred for 20 min, and freeze-dried to obtain a modified composite enzyme;

[0068] S4. Add 10 g of pretreated ginkgo leaf powder to 40 g of ionic liquid, add 2.5 g of modified complex enzyme, heat to 55 ° C, stir and extract for 3.5 h, filter, add an equal volume of ethyl acetate to the filtrate, shake and extract, let stand to separate, separate the layers, remove the solvent from the ethyl acetate layer under reduced pressure, and obtain a ginkgo organic extract;

[0069] The ionic liquid is an aqueous solution of 1-butyl-3-methylimidazolium chloride with a concentration of 7 g / L;

[0070] S5. 10 g of Danshen and 13.5 g of Gastrodia elata were mixed and dried, crushed, added to 200 mL of extraction solvent, heated to 70 ° C, stirred and extracted for 2 h, filtered, the liquid was concentrated, and dried to obtain an extract;

[0071] The extraction solvent is a mixed solvent of n-butanol, ethyl acetate and water in a volume ratio of 6:4:10;

[0072] S6. 1.5 g of drug cocrystal, 13.5 g of Ginkgo organic extract and 8.5 g of extract were stirred and mixed for 15 minutes to prepare a composition for treating vertigo.

[0073] Example 4

[0074] Compared with Example 3, the difference is that no cellulase is added in step S3.

[0075] The details are as follows:

[0076] S1. Dissolve 10 g of flunarizine in 200 mL of ethanol, dissolve 4 g of scopolamine hydrobromide and 3 g of betahistine in 200 mL of water, mix the two evenly, evaporate the solvent in an open container, filter, wash, dry, and ball-mill for 1 h to obtain a drug cocrystal;

[0077] S2. The ginkgo leaves were dried, crushed, and degreased and depigmented by adding a mixed solvent in a Soxhlet extractor for 1.5 h, filtered, and dried to obtain pretreated ginkgo leaf powder;

[0078] The mixed solvent is a mixed solvent of acetone, ethanol and water, with a volume ratio of 1:1.5:10;

[0079] S3. 27 g of pectinase was mixed into 500 mL of water, 0.35 g of manganese chloride and 0.3 g of calcium chloride were added, stirred for 20 min, and freeze-dried to obtain a modified enzyme;

[0080] S4. Add 10 g of pretreated ginkgo leaf powder to 40 g of ionic liquid, add 2.5 g of modified enzyme, heat to 55 ° C, stir and extract for 3.5 h, filter, add an equal volume of ethyl acetate to the filtrate, shake and extract, let stand to separate, separate the layers, remove the solvent from the ethyl acetate layer under reduced pressure, and obtain an organic extract of ginkgo;

[0081] The ionic liquid is an aqueous solution of 1-butyl-3-methylimidazolium chloride with a concentration of 7 g / L;

[0082] S5. 10 g of Danshen and 13.5 g of Gastrodia elata were mixed and dried, crushed, added to 200 mL of extraction solvent, heated to 70 ° C, stirred and extracted for 2 h, filtered, the liquid was concentrated, and dried to obtain an extract;

[0083] The extraction solvent is a mixed solvent of n-butanol, ethyl acetate and water in a volume ratio of 6:4:10;

[0084] S6. 1.5 g of drug cocrystal, 13.5 g of Ginkgo organic extract and 8.5 g of extract were stirred and mixed for 15 minutes to prepare a composition for treating vertigo.

[0085] Example 5

[0086] Compared with Example 3, the difference is that pectinase is not added in step S3.

[0087] The details are as follows:

[0088] S1. Dissolve 10 g of flunarizine in 200 mL of ethanol, dissolve 4 g of scopolamine hydrobromide and 3 g of betahistine in 200 mL of water, mix the two evenly, evaporate the solvent in an open container, filter, wash, dry, and ball-mill for 1 h to obtain a drug cocrystal;

[0089] S2. The ginkgo leaves were dried, crushed, and degreased and depigmented by adding a mixed solvent in a Soxhlet extractor for 1.5 h, filtered, and dried to obtain pretreated ginkgo leaf powder;

[0090] The mixed solvent is a mixed solvent of acetone, ethanol and water, with a volume ratio of 1:1.5:10;

[0091] S3. 27 g of cellulase was mixed into 500 mL of water, 0.35 g of manganese chloride and 0.3 g of calcium chloride were added, stirred and mixed for 20 min, and freeze-dried to obtain a modified enzyme;

[0092] S4. Add 10 g of pretreated ginkgo leaf powder to 40 g of ionic liquid, add 2.5 g of modified enzyme, heat to 55 ° C, stir and extract for 3.5 h, filter, add an equal volume of ethyl acetate to the filtrate, shake and extract, let stand to separate, separate the layers, remove the solvent from the ethyl acetate layer under reduced pressure, and obtain an organic extract of ginkgo;

[0093] The ionic liquid is an aqueous solution of 1-butyl-3-methylimidazolium chloride with a concentration of 7 g / L;

[0094] S5. 10 g of Danshen and 13.5 g of Gastrodia elata were mixed and dried, crushed, added to 200 mL of extraction solvent, heated to 70 ° C, stirred and extracted for 2 h, filtered, the liquid was concentrated, and dried to obtain an extract;

[0095] The extraction solvent is a mixed solvent of n-butanol, ethyl acetate and water in a volume ratio of 6:4:10;

[0096] S6. 1.5 g of drug cocrystal, 13.5 g of Ginkgo organic extract and 8.5 g of extract were stirred and mixed for 15 minutes to prepare a composition for treating vertigo.

[0097] Example 6

[0098] Compared with Example 3, the difference is that manganese chloride is not added in step S3.

[0099] The details are as follows:

[0100] S1. Dissolve 10 g of flunarizine in 200 mL of ethanol, dissolve 4 g of scopolamine hydrobromide and 3 g of betahistine in 200 mL of water, mix the two evenly, evaporate the solvent in an open container, filter, wash, dry, and ball-mill for 1 h to obtain a drug cocrystal;

[0101] S2. The ginkgo leaves were dried, crushed, and degreased and depigmented by adding a mixed solvent in a Soxhlet extractor for 1.5 h, filtered, and dried to obtain pretreated ginkgo leaf powder;

[0102] The mixed solvent is a mixed solvent of acetone, ethanol and water, with a volume ratio of 1:1.5:10;

[0103] S3. 17 g of cellulase and 10 g of pectinase were mixed into 500 mL of water, 0.65 g of calcium chloride was added, stirred for 20 min, and freeze-dried to obtain a modified composite enzyme;

[0104] S4. Add 10 g of pretreated ginkgo leaf powder to 40 g of ionic liquid, add 2.5 g of modified complex enzyme, heat to 55 ° C, stir and extract for 3.5 h, filter, add an equal volume of ethyl acetate to the filtrate, shake and extract, let stand to separate, separate the layers, remove the solvent from the ethyl acetate layer under reduced pressure, and obtain a ginkgo organic extract;

[0105] The ionic liquid is an aqueous solution of 1-butyl-3-methylimidazolium chloride with a concentration of 7 g / L;

[0106] S5. 10 g of Danshen and 13.5 g of Gastrodia elata were mixed and dried, crushed, added to 200 mL of extraction solvent, heated to 70 ° C, stirred and extracted for 2 h, filtered, the liquid was concentrated, and dried to obtain an extract;

[0107] The extraction solvent is a mixed solvent of n-butanol, ethyl acetate and water in a volume ratio of 6:4:10;

[0108] S6. 1.5 g of drug cocrystal, 13.5 g of Ginkgo organic extract and 8.5 g of extract were stirred and mixed for 15 minutes to prepare a composition for treating vertigo.

[0109] Example 7

[0110] Compared with Example 3, the difference is that calcium chloride is not added in step S3.

[0111] The details are as follows:

[0112] S1. Dissolve 10 g of flunarizine in 200 mL of ethanol, dissolve 4 g of scopolamine hydrobromide and 3 g of betahistine in 200 mL of water, mix the two evenly, evaporate the solvent in an open container, filter, wash, dry, and ball-mill for 1 h to obtain a drug cocrystal;

[0113] S2. The ginkgo leaves were dried, crushed, and degreased and depigmented by adding a mixed solvent in a Soxhlet extractor for 1.5 h, filtered, and dried to obtain pretreated ginkgo leaf powder;

[0114] The mixed solvent is a mixed solvent of acetone, ethanol and water, with a volume ratio of 1:1.5:10;

[0115] S3. 17 g of cellulase and 10 g of pectinase were mixed into 500 mL of water, 0.65 g of manganese chloride was added, stirred for 20 min, and freeze-dried to obtain a modified composite enzyme;

[0116] S4. Add 10 g of pretreated ginkgo leaf powder to 40 g of ionic liquid, add 2.5 g of modified complex enzyme, heat to 55 ° C, stir and extract for 3.5 h, filter, add an equal volume of ethyl acetate to the filtrate, shake and extract, let stand to separate, separate the layers, remove the solvent from the ethyl acetate layer under reduced pressure, and obtain a ginkgo organic extract;

[0117] The ionic liquid is an aqueous solution of 1-butyl-3-methylimidazolium chloride with a concentration of 7 g / L;

[0118] S5. 10 g of Danshen and 13.5 g of Gastrodia elata were mixed and dried, crushed, added to 200 mL of extraction solvent, heated to 70 ° C, stirred and extracted for 2 h, filtered, the liquid was concentrated, and dried to obtain an extract;

[0119] The extraction solvent is a mixed solvent of n-butanol, ethyl acetate and water in a volume ratio of 6:4:10;

[0120] S6. 1.5 g of drug cocrystal, 13.5 g of Ginkgo organic extract and 8.5 g of extract were stirred and mixed for 15 minutes to prepare a composition for treating vertigo.

[0121] Comparative Example 1

[0122] Compared with Example 3, the difference is that flunarizine is not added in step S1.

[0123] The details are as follows:

[0124] S1. Dissolve 9.7 g of anisodamine hydrobromide and 7.3 g of betahistine in 200 mL of water, evaporate the solvent in an open air, filter, wash, dry, and ball-mill for 1 h to obtain a drug cocrystal;

[0125] S2. The ginkgo leaves were dried, crushed, and degreased and depigmented by adding a mixed solvent in a Soxhlet extractor for 1.5 h, filtered, and dried to obtain pretreated ginkgo leaf powder;

[0126] The mixed solvent is a mixed solvent of acetone, ethanol and water, with a volume ratio of 1:1.5:10;

[0127] S3. 17 g of cellulase and 10 g of pectinase were mixed into 500 mL of water, 0.35 g of manganese chloride and 0.3 g of calcium chloride were added, stirred for 20 min, and freeze-dried to obtain a modified composite enzyme;

[0128] S4. Add 10 g of pretreated ginkgo leaf powder to 40 g of ionic liquid, add 2.5 g of modified complex enzyme, heat to 55 ° C, stir and extract for 3.5 h, filter, add an equal volume of ethyl acetate to the filtrate, shake and extract, let stand to separate, separate the layers, remove the solvent from the ethyl acetate layer under reduced pressure, and obtain a ginkgo organic extract;

[0129] The ionic liquid is an aqueous solution of 1-butyl-3-methylimidazolium chloride with a concentration of 7 g / L;

[0130] S5. 10 g of Danshen and 13.5 g of Gastrodia elata were mixed and dried, crushed, added to 200 mL of extraction solvent, heated to 70 ° C, stirred and extracted for 2 h, filtered, the liquid was concentrated, and dried to obtain an extract;

[0131] The extraction solvent is a mixed solvent of n-butanol, ethyl acetate and water in a volume ratio of 6:4:10;

[0132] S6. 1.5 g of drug cocrystal, 13.5 g of Ginkgo organic extract and 8.5 g of extract were stirred and mixed for 15 minutes to prepare a composition for treating vertigo.

[0133] Comparative Example 2

[0134] Compared with Example 3, the difference is that no anisodamine hydrobromide is added in step S1.

[0135] The details are as follows:

[0136] S1. Dissolve 10 g of flunarizine in 200 mL of ethanol and 7 g of betahistine in 200 mL of water, mix the two evenly, evaporate the solvent in an open air, filter, wash, dry, and ball-mill for 1 h to obtain a drug cocrystal;

[0137] S2. The ginkgo leaves were dried, crushed, and degreased and depigmented by adding a mixed solvent in a Soxhlet extractor for 1.5 h, filtered, and dried to obtain pretreated ginkgo leaf powder;

[0138] The mixed solvent is a mixed solvent of acetone, ethanol and water, with a volume ratio of 1:1.5:10;

[0139] S3. 17 g of cellulase and 10 g of pectinase were mixed into 500 mL of water, 0.35 g of manganese chloride and 0.3 g of calcium chloride were added, stirred for 20 min, and freeze-dried to obtain a modified composite enzyme;

[0140] S4. Add 10 g of pretreated ginkgo leaf powder to 40 g of ionic liquid, add 2.5 g of modified complex enzyme, heat to 55 ° C, stir and extract for 3.5 h, filter, add an equal volume of ethyl acetate to the filtrate, shake and extract, let stand to separate, separate the layers, remove the solvent from the ethyl acetate layer under reduced pressure, and obtain a ginkgo organic extract;

[0141] The ionic liquid is an aqueous solution of 1-butyl-3-methylimidazolium chloride with a concentration of 7 g / L;

[0142] S5. 10 g of Danshen and 13.5 g of Gastrodia elata were mixed and dried, crushed, added to 200 mL of extraction solvent, heated to 70 ° C, stirred and extracted for 2 h, filtered, the liquid was concentrated, and dried to obtain an extract;

[0143] The extraction solvent is a mixed solvent of n-butanol, ethyl acetate and water in a volume ratio of 6:4:10;

[0144] S6. 1.5 g of drug cocrystal, 13.5 g of Ginkgo organic extract and 8.5 g of extract were stirred and mixed for 15 minutes to prepare a composition for treating vertigo.

[0145] Comparative Example 3

[0146] Compared with Example 3, the difference is that betahistine is not added in step S1.

[0147] The details are as follows:

[0148] S1. Dissolve 10 g of flunarizine in 200 mL of ethanol and 7 g of anisodamine hydrobromide in 200 mL of water, mix the two evenly, evaporate the solvent in an open air, filter, wash, dry, and ball-mill for 1 h to obtain a drug cocrystal;

[0149] S2. The ginkgo leaves were dried, crushed, and degreased and depigmented by adding a mixed solvent in a Soxhlet extractor for 1.5 h, filtered, and dried to obtain pretreated ginkgo leaf powder;

[0150] The mixed solvent is a mixed solvent of acetone, ethanol and water, with a volume ratio of 1:1.5:10;

[0151] S3. 17 g of cellulase and 10 g of pectinase were mixed into 500 mL of water, 0.35 g of manganese chloride and 0.3 g of calcium chloride were added, stirred for 20 min, and freeze-dried to obtain a modified composite enzyme;

[0152] S4. Add 10 g of pretreated ginkgo leaf powder to 40 g of ionic liquid, add 2.5 g of modified complex enzyme, heat to 55 ° C, stir and extract for 3.5 h, filter, add an equal volume of ethyl acetate to the filtrate, shake and extract, let stand to separate, separate the layers, remove the solvent from the ethyl acetate layer under reduced pressure, and obtain a ginkgo organic extract;

[0153] The ionic liquid is an aqueous solution of 1-butyl-3-methylimidazolium chloride with a concentration of 7 g / L;

[0154] S5. 10 g of Danshen and 13.5 g of Gastrodia elata were mixed and dried, crushed, added to 200 mL of extraction solvent, heated to 70 ° C, stirred and extracted for 2 h, filtered, the liquid was concentrated, and dried to obtain an extract;

[0155] The extraction solvent is a mixed solvent of n-butanol, ethyl acetate and water in a volume ratio of 6:4:10;

[0156] S6. 1.5 g of drug cocrystal, 13.5 g of Ginkgo organic extract and 8.5 g of extract were stirred and mixed for 15 minutes to prepare a composition for treating vertigo.

[0157] Comparative Example 4

[0158] Compared with Example 3, the difference is that manganese chloride and calcium chloride are not added in step S3.

[0159] The details are as follows:

[0160] S1. Dissolve 10 g of flunarizine in 200 mL of ethanol, dissolve 4 g of scopolamine hydrobromide and 3 g of betahistine in 200 mL of water, mix the two evenly, evaporate the solvent in an open container, filter, wash, dry, and ball-mill for 1 h to obtain a drug cocrystal;

[0161] S2. The ginkgo leaves were dried, crushed, and degreased and depigmented by adding a mixed solvent in a Soxhlet extractor for 1.5 h, filtered, and dried to obtain pretreated ginkgo leaf powder;

[0162] The mixed solvent is a mixed solvent of acetone, ethanol and water, with a volume ratio of 1:1.5:10;

[0163] S3. 17 g of cellulase and 10 g of pectinase were mixed and added to 500 mL of water, stirred for 20 min, and freeze-dried to obtain a composite enzyme;

[0164] S4. Add 10 g of pretreated ginkgo leaf powder to 40 g of ionic liquid, add 2.5 g of complex enzyme, heat to 55 ° C, stir and extract for 3.5 h, filter, add an equal volume of ethyl acetate to the filtrate, shake and extract, let stand and separate, separate the layers, remove the solvent under reduced pressure in the ethyl acetate layer, and obtain a ginkgo organic extract;

[0165] The ionic liquid is an aqueous solution of 1-butyl-3-methylimidazolium chloride with a concentration of 7 g / L;

[0166] S5. 10 g of Danshen and 13.5 g of Gastrodia elata were mixed and dried, crushed, added to 200 mL of extraction solvent, heated to 70 ° C, stirred and extracted for 2 h, filtered, the liquid was concentrated, and dried to obtain an extract;

[0167] The extraction solvent is a mixed solvent of n-butanol, ethyl acetate and water in a volume ratio of 6:4:10;

[0168] S6. 1.5 g of drug cocrystal, 13.5 g of Ginkgo organic extract and 8.5 g of extract were stirred and mixed for 15 minutes to prepare a composition for treating vertigo.

[0169] Comparative Example 5

[0170] Compared with Example 3, the difference is that no modified composite enzyme is added in step S4.

[0171] The details are as follows:

[0172] S1. Dissolve 10 g of flunarizine in 200 mL of ethanol, dissolve 4 g of scopolamine hydrobromide and 3 g of betahistine in 200 mL of water, mix the two evenly, evaporate the solvent in an open container, filter, wash, dry, and ball-mill for 1 h to obtain a drug cocrystal;

[0173] S2. The ginkgo leaves were dried, crushed, and degreased and depigmented by adding a mixed solvent in a Soxhlet extractor for 1.5 h, filtered, and dried to obtain pretreated ginkgo leaf powder;

[0174] The mixed solvent is a mixed solvent of acetone, ethanol and water, with a volume ratio of 1:1.5:10;

[0175] S3. Add 10 g of pretreated ginkgo leaf powder to 40 g of ionic liquid, heat to 55 ° C, stir and extract for 3.5 h, filter, add an equal volume of ethyl acetate to the filtrate, shake and extract, let stand and separate, separate the layers, remove the solvent under reduced pressure in the ethyl acetate layer, and obtain a ginkgo organic extract;

[0176] The ionic liquid is an aqueous solution of 1-butyl-3-methylimidazolium chloride with a concentration of 7 g / L;

[0177] S4. 10 g of Danshen and 13.5 g of Gastrodia elata were mixed and dried, crushed, added to 200 mL of extraction solvent, heated to 70 ° C, stirred and extracted for 2 h, filtered, the liquid was concentrated, and dried to obtain an extract;

[0178] The extraction solvent is a mixed solvent of n-butanol, ethyl acetate and water in a volume ratio of 6:4:10;

[0179] S5. 1.5 g of drug cocrystal, 13.5 g of Ginkgo organic extract and 8.5 g of extract were stirred and mixed for 15 minutes to prepare a composition for treating vertigo.

[0180] Comparative Example 6

[0181] Compared with Example 3, the difference is that in step S4, the ionic liquid is replaced by an equal amount of water.

[0182] The details are as follows:

[0183] S1. Dissolve 10 g of flunarizine in 200 mL of ethanol, dissolve 4 g of scopolamine hydrobromide and 3 g of betahistine in 200 mL of water, mix the two evenly, evaporate the solvent in an open container, filter, wash, dry, and ball-mill for 1 h to obtain a drug cocrystal;

[0184] S2. The ginkgo leaves were dried, crushed, and degreased and depigmented by adding a mixed solvent in a Soxhlet extractor for 1.5 h, filtered, and dried to obtain pretreated ginkgo leaf powder;

[0185] The mixed solvent is a mixed solvent of acetone, ethanol and water, with a volume ratio of 1:1.5:10;

[0186] S3. 17 g of cellulase and 10 g of pectinase were mixed into 500 mL of water, 0.35 g of manganese chloride and 0.3 g of calcium chloride were added, stirred for 20 min, and freeze-dried to obtain a modified composite enzyme;

[0187] S4. Add 10 g of pretreated ginkgo leaf powder to 40 mL of water, add 2.5 g of modified complex enzyme, heat to 55 ° C, stir and extract for 3.5 h, filter, add an equal volume of ethyl acetate to the filtrate, shake and extract, let stand to separate the layers, separate the layers, remove the solvent under reduced pressure in the ethyl acetate layer, and obtain a ginkgo organic extract;

[0188] S5. 10 g of Danshen and 13.5 g of Gastrodia elata were mixed and dried, crushed, added to 200 mL of extraction solvent, heated to 70 ° C, stirred and extracted for 2 h, filtered, the liquid was concentrated, and dried to obtain an extract;

[0189] The extraction solvent is a mixed solvent of n-butanol, ethyl acetate and water in a volume ratio of 6:4:10;

[0190] S6. 1.5 g of drug cocrystal, 13.5 g of Ginkgo organic extract and 8.5 g of extract were stirred and mixed for 15 minutes to prepare a composition for treating vertigo.

[0191] Comparative Example 7

[0192] Compared with Example 3, the difference is that no drug co-crystal is added in step S5.

[0193] The details are as follows:

[0194] S1. The ginkgo leaves were dried, crushed, and degreased and depigmented by adding a mixed solvent in a Soxhlet extractor for 1.5 h, filtered, and dried to obtain pretreated ginkgo leaf powder;

[0195] The mixed solvent is a mixed solvent of acetone, ethanol and water, with a volume ratio of 1:1.5:10;

[0196] S2. 17 g of cellulase and 10 g of pectinase were mixed into 500 mL of water, 0.35 g of manganese chloride and 0.3 g of calcium chloride were added, stirred for 20 min, and freeze-dried to obtain a modified composite enzyme;

[0197] S3. Add 10 g of pretreated ginkgo leaf powder to 40 g of ionic liquid, add 2.5 g of modified complex enzyme, heat to 55 ° C, stir and extract for 3.5 h, filter, add an equal volume of ethyl acetate to the filtrate, shake and extract, let stand to separate, separate the layers, remove the solvent from the ethyl acetate layer under reduced pressure to obtain an organic extract of ginkgo;

[0198] The ionic liquid is an aqueous solution of 1-butyl-3-methylimidazolium chloride with a concentration of 7 g / L;

[0199] S4. 10 g of Danshen and 13.5 g of Gastrodia elata were mixed and dried, crushed, added to 200 mL of extraction solvent, heated to 70 ° C, stirred and extracted for 2 h, filtered, the liquid was concentrated, and dried to obtain an extract;

[0200] The extraction solvent is a mixed solvent of n-butanol, ethyl acetate and water in a volume ratio of 6:4:10;

[0201] S5. 13.5 g of the organic extract of Ginkgo biloba and 8.5 g of the extract were stirred and mixed for 15 min to prepare a composition for treating vertigo.

[0202] Test Example 1

[0203] SD rats were selected, SPF grade, male, with a body weight of 200-220g. Positive drugs were selected from difenidol tablets for the prevention and treatment of vertigo. After 4 days of adaptive feeding, they were randomly divided into sham operation group, model group, difenidol (15mg / kg) group, embodiment 1-7 group and comparative example 1-7 group (20mg / kg), 10 in each group. Each administration group rat was gavaged with the test substance, 1 time / d, and continuously administered for 7d, and the administration volume was 10mL / kg. The model group and the sham operation group were gavaged with equal volume of purified water. After daily administration for 1h, the jumping platform escape electrical stimulation reflex training was carried out: the rat was placed in the jumping platform instrument, and electrical stimulation was continuously given for 5min after adaptation for 3min, with an electrical stimulation voltage of 30V and a frequency of 50Hz. The training was successful when the rat jumped onto the platform and maintained for 30s, and trained twice a day for 3d continuously to establish a firm conditioned reflex of rats to escape electrical stimulation. On the 7th day, rats were anesthetized by isoflurane inhalation, and the right common carotid artery and right subclavian artery were ligated to reproduce the rat posterior circulation ischemia vertigo model. The sham operation group only threaded the wire without ligation. The drug was administered after the rats woke up. One hour after the drug administration, the rats were placed in a rotator and rotated at a constant speed of 500r / min for 30s and stopped suddenly. They were immediately placed in a jumping platform. The time required for the rats to jump onto the platform for the first time and not fall within 30s from electrical stimulation was recorded (excluding the time the rats were on the platform), which was recorded as the incubation period.

[0204] The results are shown in Table 1.

[0205] Table 1

[0206] Group Jumping latency (s) Sham operation group 12.42±5.19 Model Group 61.35±45.71 Difendoni Formation 9.10±8.49 Example 1 10.04±6.98 Example 2 9.57±8.15 Example 3 9.14±7.82 Example 4 12.62±9.35 Example 5 13.19±10.12 Example 6 10.84±8.95 Example 7 10.92±9.45 Comparative Example 1 14.78±10.11 Comparative Example 2 16.51±11.53 Comparative Example 3 15.78±10.29 Comparative Example 4 15.78±10.14 Comparative Example 5 22.67±10.94 Comparative Example 6 16.52±11.23 Comparative Example 7 28.78±12.46

[0207] Note: Compared with the sham operation group, * means P < 0.05; compared with the model group, # means P < 0.05.

[0208] It can be seen from the above table that the compositions for treating vertigo prepared in Examples 1-3 of the present invention can significantly reduce the platform jumping latency of rats.

[0209] Test Example 2

[0210] Select 65 SD rats, SPF level, male, body weight 200-220g. After 10d of adaptive feeding, randomly divided into model group, embodiment 1-7 group, comparative example 1-7 group (20mg / kg). Oral administration, 1 time / d, 3d of administration in total, model group oral administration of equal volume of purified water. After the 3rd day of administration, 1h adopts isoflurane inhalation anesthesia rats, separates the right common carotid artery and the right subclavian artery of rats, and threading is standby (not ligated). Rats are fixed on a brain stereotaxic instrument, using flat skull position, 10.5mm from the anterior fontanelle, 2.3mm on the right side of the raphe, 5.0mm deep, locate the right vestibular nerve nucleus of rats, use Doppler blood flowmeter, measure the right vestibular nerve nucleus tissue blood flow, after blood flow is stable, describe the normal blood flow curve, and record the average blood flow value of 1min as the basal blood flow. Then, the right common carotid artery and right subclavian artery were ligated, and the blood flow curve was recorded for 30 minutes. The blood flow values ​​10, 20, and 30 minutes after artery ligation were recorded (the average blood flow value of 1 minute was recorded at each time point), and the blood flow decrease rate at each time point was calculated according to formula (1).

[0211] Blood flow decrease rate = (blood flow at different time points – basic blood flow) / basic blood flow × 100%

[0212] The results are shown in Table 2.

[0213] Table 2

[0214]

[0215]

[0216] It can be seen from the above table that the compositions for treating vertigo prepared in Examples 1-3 of the present invention can significantly increase the blood flow of the vestibular nerve nucleus after cerebral ischemia, thereby improving the symptoms of ischemic vertigo.

[0217] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principle of the present invention should be included in the protection scope of the present invention.

Claims

1. A method for preparing a composition for treating vertigo, characterized in that: In order to prepare flunarizine-anisodamine hydrobromide-betahistine drug cocrystal, ginkgo leaves are defatted and depigmented, extracted with a metal ion-modified composite enzyme catalyzed ionic liquid, and extracted with ethyl acetate to obtain a ginkgo organic extract, and then salvia miltiorrhiza and gastrodia elata are extracted with an extraction solvent to obtain an extract, which is uniformly mixed with the ginkgo organic extract and the cocrystal to obtain a composition for treating vertigo.

2. The preparation method according to claim 1, characterized in that: The following steps are involved: S1. dissolving flunarizine in ethanol, dissolving anisodamine hydrobromide and betahistine in water, mixing the two evenly, evaporating the solvent in an open manner, filtering, washing, drying, and ball milling to obtain a drug cocrystal; S2. The ginkgo leaves were dried, crushed, added to a mixed solvent in a Soxhlet extractor for degreasing and depigmentation, filtered, and dried to obtain pretreated ginkgo leaf powder; S3. The cellulase and pectinase were mixed into water, manganese ions and calcium ions were added, the mixture was stirred and evenly mixed, and freeze-dried to obtain a modified composite enzyme; S4. The pretreated ginkgo leaf powder is added to the ionic liquid, the modified complex enzyme is added, the extraction is heated and stirred, the filtrate is added to ethyl acetate, the extraction is shaken, the layers are allowed to stand, the layers are separated, and the solvent is removed from the ethyl acetate layer under reduced pressure to obtain an organic extract of ginkgo; S5. The Danshen and Gastrodia elata were mixed and dried, crushed, added to the extraction solvent, heated and stirred for extraction, filtered, the liquid was concentrated, and dried to obtain an extract; S6. Evenly mix the drug co-crystal, ginkgo organic extract and extract to prepare a composition for treating vertigo.

3. The preparation method according to claim 2, characterized in that: The mass ratio of flunarizine, anisodamine hydrobromide and betahistine in step S1 is 10:3-5:2-4.

4. The preparation method according to claim 2, characterized in that: The mixed solvent in step S2 is a mixed solvent of acetone, ethanol and water, with a volume ratio of 1:1-2:10, and the degreasing and depigmenting time is 1-2h.

5. The preparation method according to claim 2, characterized in that: In step S3, the manganese ion is manganese chloride, the calcium ion is calcium chloride, and the mass ratio of the cellulase, pectinase, manganese chloride and calcium chloride is 15-20:7-12:0.3-0.4:0.1-0.

5.

6. The preparation method according to claim 2, characterized in that: The ionic liquid in step S4 is an aqueous solution of 1-butyl-3-methylimidazolium chloride or 1-ethyl-3-methylimidazolium bromide with a concentration of 5-10 g / L. The mass ratio of the pretreated ginkgo leaf powder, the ionic liquid and the modified composite enzyme is 10:30-50:2-3. The temperature of the heated stirring extraction is 50-60°C and the time is 3-4h.

7. The preparation method according to claim 2, characterized in that: In step S5, the mass ratio of Danshen and Gastrodia elata is 10:12-15, the extraction solvent is a mixed solvent of n-butanol, ethyl acetate and water, the volume ratio is 5-7:3-5:10, the temperature of the heating and stirring extraction is 65-75°C, and the time is 1-3h.

8. The preparation method according to claim 2, characterized in that: The mass ratio of the drug cocrystal, the ginkgo organic extract and the extract in step S6 is 1-2:12-15:7-10.

9. The preparation method according to claim 2, characterized in that: The specific steps include: S1. Dissolve 10 parts by weight of flunarizine in ethanol, dissolve 3-5 parts by weight of anisodamine hydrobromide and 2-4 parts by weight of betahistine in water, mix the two evenly, evaporate the solvent in an open state, filter, wash, dry, and ball-mill to obtain a drug cocrystal; S2. The ginkgo leaves were dried, crushed, and degreased and depigmented by adding a mixed solvent in a Soxhlet extractor for 1-2h, filtered, and dried to obtain pretreated ginkgo leaf powder; The mixed solvent is a mixed solvent of acetone, ethanol and water, with a volume ratio of 1:1-2:10; S3. 15-20 parts by weight of cellulase and 7-12 parts by weight of pectinase were mixed into water, 0.3-0.4 parts by weight of manganese chloride and 0.1-0.5 parts by weight of calcium chloride were added, stirred and mixed, and freeze-dried to obtain a modified composite enzyme; S4. Add 10 parts by weight of pretreated ginkgo leaf powder to 30-50 parts by weight of ionic liquid, add 2-3 parts by weight of modified complex enzyme, heat to 50-60°C, stir and extract for 3-4h, filter, add an equal volume of ethyl acetate to the filtrate, shake and extract, let stand to separate, separate the layers, remove the solvent from the ethyl acetate layer under reduced pressure, and obtain an organic extract of ginkgo; S5. 10 parts by weight of Danshen, 12-15 parts by weight of Gastrodia elata were mixed and dried, crushed, added to the extraction solvent, heated to 65-75 ° C, stirred for extraction for 1-3h, filtered, the liquid was concentrated, and dried to obtain an extract; The extraction solvent is a mixed solvent of n-butanol, ethyl acetate and water, with a volume ratio of 5-7:3-5:10; S6. Evenly mix 1-2 parts by weight of the drug co-crystal, 12-15 parts by weight of the ginkgo organic extract and 7-10 parts by weight of the extract to prepare a composition for treating vertigo.

10. A composition for treating vertigo obtained by the preparation method according to any one of claims 1 to 9.

Citation Information

Patent Citations

  • Applications of ginkgo terpene lactone in preparation of drugs and health products for preventing and / or treating vertigo

    CN110433157A

  • Novel flunarizine salt forms and methods of making and using the same

    US20080200474A1